12390 EL CAMINO REAL, SAN DIEGO, CA
James Daly Elected to Board of Directors at Halozyme Therapeutics
Halozyme Therapeutics Completes $1.5 Billion Convertible Notes Offering
Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
Director Appointment - Dannielle Appelhans Elected to Board of Directors
Reports Record Second Quarter 2026 Results, Beats Estimates and Raises Full Year 2026 Financial Guidance
Departure of Cortney Caudill as COO at Halozyme Therapeutics
REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Amended Tender Offer Statement by Third Party